Affordable Access

Publisher Website

Novel Antibody Approaches for T-Cell Lymphomas

Authors
Journal
Clinical Lymphoma & Myeloma
1557-9190
Publisher
Elsevier - CIG Media Group LP
Volume
8
Identifiers
DOI: 10.3816/clm.2008.s.016
Keywords
  • Contributions
Disciplines
  • Biology
  • Medicine

Abstract

Abstract T-cell lymphomas are biologically more aggressive—and less responsive than their B-cell counterparts—to conventional chemotherapy. The understanding of the normal physiology of T-cell signaling as well as the pathophysiology of T-cell neoplasia has advanced dramatically in the past decade. Thus, a number of novel cell surface therapeutic targets specific for T-cells have been identified and evaluated as potential monoclonal antibody (MoAb)—based therapeutic targets. Herein, we review a number of these cell surface targets and discuss the development and the clinical evaluation of MoAb therapies directed against these antigens.

There are no comments yet on this publication. Be the first to share your thoughts.

Statistics

Seen <100 times
0 Comments

More articles like this

Novel antibody approaches for T-cell lymphomas.

on Clinical lymphoma & myeloma December 2008

An immunohistochemical study of TAL-1 protein expr...

on The Journal of pathology March 1996

Anti-CD20 antibody therapy for B-cell lymphomas.

on New England Journal of Medicin... May 24, 2012
More articles like this..